Investing
590 Articles
Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. …
All three major US indexes opened higher this morning, but enthusiasm tapered off quickly and steadily, if not sharply. A…
It is not that often that investors get to clean up in a merger arbitrage spread any longer. The buyout…
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking…
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of…
You know how stocks sometimes react to news on peers… Today we are again seeing a run in the world…
Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C…
Deal makers were busy over the weekend. Strategic considerations were more the driver of activity than an improved economy, however.…
http://platform.twitter.com/widgets/hub.1324331373.html The U.S. may start legal proceedings against Swiss financial firm Wegelin & Co. based on beliefs that it helped…
Bristol-Myers (NYSE: BMY) will buy Inhibitex (NASDAQ: IHNX) for $26 a share about 2.5x what the smaller company’s shares traded…
The EU continues to work on its bailout fund and may ask the IMF for help. (Reuters) American Airlines parent…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
The DJIA jumped above 12,000 in the opening minutes of trading this morning and had topped 12,200 by mid-afternoon. European…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better…
Our top personal finance-related articles today. Your wallet will thank you later.